Đăng xuất
X-linked hypophosphataemia
Adult: Initially, 1 mg/kg every 4 weeks, round dose to the nearest 10 mg. Max: 90 mg. Dose may be adjusted, interrupted, or maintained based on serum phosphorus level (refer to detailed product guideline).
Child: 1-17 years Initially, 0.8 mg/kg every 2 weeks, round dose to the nearest 10 mg. Max: 90 mg. Alternative dosage recommendation: 6 months to <18 years <10 kg: Initially, 1 mg/kg every 2 weeks, round dose to the nearest 1 mg; ≥10 kg: 0.8 mg/kg every 2 weeks, round dose to the nearest 10 mg; Max: 90 mg. All doses may be adjusted, interrupted, or maintained based on serum phosphorus level. Treatment or dosage recommendations may vary among countries. Refer to detailed product guideline.
Child: 1-17 years Initially, 0.8 mg/kg every 2 weeks, round dose to the nearest 10 mg. Max: 90 mg. Alternative dosage recommendation: 6 months to <18 years <10 kg: Initially, 1 mg/kg every 2 weeks, round dose to the nearest 1 mg; ≥10 kg: 0.8 mg/kg every 2 weeks, round dose to the nearest 10 mg; Max: 90 mg. All doses may be adjusted, interrupted, or maintained based on serum phosphorus level. Treatment or dosage recommendations may vary among countries. Refer to detailed product guideline.
Subcutaneous
Fibroblast growth factor 23 (FGF23)-related hypophosphataemia in tumour-induced osteomalacia
Adult: In cases associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised: Initially, 0.5 mg/kg every 4 weeks, round dose to the nearest 10 mg. Max: 2 mg/kg (not exceeding 180 mg) every 2 weeks. Dose may be adjusted, interrupted, or maintained based on serum phosphorus level (refer to detailed product guideline).
Child: In cases associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised: 2-17 years Initially, 0.4 mg/kg every 2 weeks, round dose to the nearest 10 mg. Max: 2 mg/kg (not exceeding 180 mg) every 2 weeks. Dose may be adjusted, interrupted, or maintained based on serum phosphorus level (refer to detailed product guideline).
Child: In cases associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised: 2-17 years Initially, 0.4 mg/kg every 2 weeks, round dose to the nearest 10 mg. Max: 2 mg/kg (not exceeding 180 mg) every 2 weeks. Dose may be adjusted, interrupted, or maintained based on serum phosphorus level (refer to detailed product guideline).
